Patents by Inventor Markos LEGGAS

Markos LEGGAS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mithramycin derivatives having increased selectivity and anti-cancer activity
    Patent number: 11692003
    Abstract: Mithramycin (MTM) short side chain ketone (SK) derivatives and MTM short side chain diketone (SDK) derivatives are provided. The MTM SK and MTM SDK derivatives are useful for treatment of cancer or neuro-diseases associated with an aberrant erythroblast transformation-specific transcription factor. Unique MTM SK and MTM SDK derivatives have increased selectively toward ETS transcription factor.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: July 4, 2023
    Assignee: University of Kentucky Research Foundation
    Inventors: Jurgen Rohr, Oleg Tsodikov, Markos Leggas, Caixia Hou, Joseph Eckenrode, Prithiba Mitra, Abhisek Mandal
  • MITHRAMYCIN OXIME DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY
    Publication number: 20230132854
    Abstract: Compounds described herein are mithramycin (MTM) oxide (OX) derivatives. These compounds are useful for treatment of cancers and neuro-diseases.
    Type: Application
    Filed: October 11, 2022
    Publication date: May 4, 2023
    Inventors: Jon S. Thorson, Jurgen Rohr, Markos Leggas, Joseph M. Eckenrode, Yinan Zhang, Yang Liu, Jianjun Zhang, Khaled Attia Shaaban Mahmoud
  • Mithramycin oxime derivatives having increased selectivity and anti-cancer activity
    Patent number: 11466045
    Abstract: Compounds described herein are mithramycin (MTM) oxide (OX) derivatives and MTM Hydrazine (HY) derivatives. These compounds are useful for treatment of cancers and neuro-diseases.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: October 11, 2022
    Assignee: University of Kentucky Research Foundation
    Inventors: Jon S. Thorson, Jurgen Rohr, Markos Leggas, Joseph M. Eckenrode, Yinan Zhang, Yang Liu, Jianjun Zhang, Khaled Attia Shaaban Mahmoud
  • MITHRAMYCIN DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY
    Publication number: 20220033429
    Abstract: Mithramycin (MTM) short side chain ketone (SK) derivatives and MTM short side chain diketone (SDK) derivatives are provided. The MTM SK and MTM SDK derivatives are useful for treatment of cancer or neuro-diseases associated with an aberrant erythroblast transformation-specific transcription factor. Unique MTM SK and MTM SDK derivatives have increased selectively toward ETS transcription factor.
    Type: Application
    Filed: September 20, 2019
    Publication date: February 3, 2022
    Inventors: Jurgen Rohr, Oleg Tsodikov, Markos Leggas, Caixia Hou, Joseph Eckenrode, Prithiba Mitra, Abhisek Mandal
  • Mithramycin derivatives having increased selectivity and anti-cancer activity
    Patent number: 11224609
    Abstract: Mithramycin side chain carboxylic acid (MTM-SA) derivative are provided, which include a substituted amino acid derivative, a substituted amino acid dipeptide derivative, or an unsubstituted dipeptide derivative. The MTM-SA derivatives are useful for treatment of cancer or neuro-diseases associated with an aberrant erythroblast transformation-specific transcription factor. Unique MTM-SA derivatives have increased selectively toward ETS transcription factor.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: January 18, 2022
    Assignee: University of Kentucky Research Foundation
    Inventors: Jurgen Rohr, Oleg Tsodikov, Markos Leggas, Caixia Hou, Joseph Eckenrode, Prithiba Mitra, Abhisek Mandal
  • MITHRAMYCIN OXIME AND HYDRAZINE DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY
    Publication number: 20200131218
    Abstract: Compounds described herein are mithramycin (MTM) oxide (OX) derivatives and MTM Hydrazine (HY) derivatives. These compounds are useful for treatment of cancers and neuro-diseases.
    Type: Application
    Filed: October 31, 2019
    Publication date: April 30, 2020
    Inventors: Jon S. Thorson, Jurgen Rohr, Markos Leggas, Joseph M. Eckenrode, Yinan Zhang, Yang Liu, Jianjun Zhang, Khaled Attia Shaaban Mahmoud
  • Phenylethynyl-substituted benzenes and heterocycles for the treatment of cancer
    Patent number: 10449186
    Abstract: Halogenated phenylethynyl-substituted heterocycles that possess either an N-alkylamino or N,N-dialkylamino group attached to the heterocycle or halogenated phenylethynyl-substituted benzenes that a nitrogen-containing heterocycle attached to the benzene inhibit the proliferation cancer cells and are useful antineoplastic agents.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: October 22, 2019
    Assignee: University of Kentucky Research Foundation
    Inventors: David S. Watt, Chunming Liu, Vitaliy M. Sviripa, Wen Zhang, Markos Leggas
  • MITHRAMYCIN DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY
    Publication number: 20190083519
    Abstract: Mithramycin side chain carboxylic acid (MTM-SA) derivative are provided, which include a substituted amino acid derivative, a substituted amino acid dipeptide derivative, or an unsubstituted dipeptide derivative. The MTM-SA derivatives are useful for treatment of cancer or neuro-diseases associated with an aberrant erythroblast transformation-specific transcription factor. Unique MTM-SA derivatives have increased selectively toward ETS transcription factor.
    Type: Application
    Filed: September 5, 2018
    Publication date: March 21, 2019
    Inventors: Jurgen Rohr, Oleg Tsodikov, Markos Leggas, Caixia Hou, Joseph Eckenrode, Prithiba Mitra, Abhisek Mandal
  • PHENYLETHYNYL-SUBSTITUTED BENZENES AND HETEROCYCLES FOR THE TREATMENT OF CANCER
    Publication number: 20180369222
    Abstract: Halogenated phenylethynyl-substituted heterocycles that possess either an N-alkylamino or N,N-dialkylarnino group attached to the heterocycle or halogenated phenylethynyl-substituted benzenes that a nitrogen-containing heterocycle attached to the benzene inhibit the proliferation cancer cells and are useful antineoplastic agents.
    Type: Application
    Filed: May 10, 2018
    Publication date: December 27, 2018
    Inventors: David S. WATT, Chunming LIU, Vitaliy M. SVIRIPA, Wen ZHANG, Markos LEGGAS
  • PYRANONAPHTHOQUINONE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20180055816
    Abstract: Provided herein are pyranonaphthoquinone compounds and methods of using pyranonaphthoquinone compounds. The method of using the pyranonaphthoquinone compounds includes selectively inhibiting 4E-BP1 phosphorylation by administering at least one pyranonaphthoquinone or pyranonaphthoquinone analog to a subject in need thereof.
    Type: Application
    Filed: August 4, 2017
    Publication date: March 1, 2018
    Inventors: Jon S. Thorson, Qing-Bai She, Bradley D. Anderson, Qing Ye, Markos Leggas, Yinan Zhang
  • Semi-synthetic mithramycin derivatives with anti-cancer activity
    Patent number: 9447135
    Abstract: Mithramycin derivatives and their pharmaceutically acceptable salts are disclosed. The mithramycin derivatives can be used in the treatment of Ewing sarcoma or other cancer or neuro-disease associated with an aberrant erythroblast transformation-specific transcription factor.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: September 20, 2016
    Assignee: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
    Inventors: Jurgen T. Rohr, Daniel Scott, Markos Leggas, Jhong-Min Chen, Oleg V. Tsodikov
  • SEMI-SYNTHETIC MITHRAMYCIN DERIVATIVES WITH ANTI-CANCER ACTIVITY
    Publication number: 20160024130
    Abstract: Mithramycin derivatives and their pharmaceutically acceptable salts are disclosed. The mithramycin derivatives can be used in the treatment of Ewing sarcoma or other cancer or neuro-disease associated with an aberrant erythroblast transformation-specific transcription factor.
    Type: Application
    Filed: May 20, 2015
    Publication date: January 28, 2016
    Inventors: Jurgen T. ROHR, Daniel SCOTT, Markos LEGGAS, Jhong-Min CHEN, Oleg V. TSODIKOV